Meeting
2024 ASCO Annual Meeting
Phase II trial of immunotherapeutic HPV vaccine PRGN-2009 with pembrolizumab before standard treatment in subjects with newly diagnosed HPV-associated oropharyngeal cancer.
Authors
Dara Mark Bracken-Clarke
Center for Immuno-Oncology, CCR, NCI, NIH, Bethesda, MD
Dara Mark Bracken-Clarke , Clint Allen , Elisabetta Xue , Marissa Mallek , Lisa M. Cordes , Seth M. Steinberg , Jenn Marte , Jason M. Redman , Danielle M. Pastor , Renee N. Donahue , Jeffrey Schlom , James L. Gulley , Charalampos S. Floudas
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT05996523
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr TPS6124)
DOI
10.1200/JCO.2024.42.16_suppl.TPS6124
Abstract #
TPS6124
Poster Bd #
434b
Abstract Disclosures
Similar Posters
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Neoadjuvant combination immunotherapy with pembrolizumab and high dose IFN-α2b in locally/regionally advanced melanoma.
First Author: Ahmad A. Tarhini
Poster
2017 ASCO Annual Meeting
Association of T-cell infiltration assessed in pretherapeutic biopsies (PTB) of patients with locally advanced rectal adenocarcinoma (LARC) with tumor response and relapse after chemoradiotherapy (CRT) and rectal surgery.
First Author: Marc Van Den Eynde
Poster
2015 ASCO Annual Meeting
Window of opportunity trial of HPV E7 antigen-expressing Listeria-based therapeutic vaccination prior to robotic surgery for HPV-positive oropharyngeal cancer.
First Author: Brett Miles
Poster
2024 ASCO Annual Meeting
Perioperative pembrolizumab and lenvatinib for resectable hepatocellular carcinoma: A single-arm, multi-center, phase II trial (NeoLEAP-HCC).
First Author: Hui-Chuan Sun